JP2023546970A - 高血圧のためのcyp11b2ベータヒドロキシラーゼ阻害剤 - Google Patents
高血圧のためのcyp11b2ベータヒドロキシラーゼ阻害剤 Download PDFInfo
- Publication number
- JP2023546970A JP2023546970A JP2023525457A JP2023525457A JP2023546970A JP 2023546970 A JP2023546970 A JP 2023546970A JP 2023525457 A JP2023525457 A JP 2023525457A JP 2023525457 A JP2023525457 A JP 2023525457A JP 2023546970 A JP2023546970 A JP 2023546970A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- cyp
- plasma
- hydroxylase inhibitor
- renin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105745P | 2020-10-26 | 2020-10-26 | |
| US63/105,745 | 2020-10-26 | ||
| US202163223719P | 2021-07-20 | 2021-07-20 | |
| US63/223,719 | 2021-07-20 | ||
| PCT/US2021/056499 WO2022093714A1 (en) | 2020-10-26 | 2021-10-25 | Cyp11b2 beta hydroxylase inhibitors for hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546970A true JP2023546970A (ja) | 2023-11-08 |
| JP2023546970A5 JP2023546970A5 (cg-RX-API-DMAC7.html) | 2024-10-30 |
Family
ID=81384356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525457A Pending JP2023546970A (ja) | 2020-10-26 | 2021-10-25 | 高血圧のためのcyp11b2ベータヒドロキシラーゼ阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240009201A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4232011A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023546970A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022093714A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230069126A (ko) * | 2020-09-15 | 2023-05-18 | 미쓰비시 타나베 파마 코퍼레이션 | 트리아진 화합물의 염, 그 결정형 및 제조 방법 |
| KR20240052937A (ko) * | 2021-07-20 | 2024-04-23 | 미네랄리스 테라퓨틱스, 아이엔씨. | 이치환된 1, 2, 4-트리아진 화합물의 염을 포함하는 가용성 약제학적 조성물 |
| EP4466021A4 (en) * | 2022-01-19 | 2026-01-14 | Mineralys Therapeutics Inc | METHODS OF TREATING HYPERTENSION BY PERIODIC SUPPRESSION OF ALDOSTERONE SYNTHASE |
| EP4577217A4 (en) * | 2022-08-23 | 2026-08-12 | Mineralys Therapeutics Inc | METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC |
| KR20250053914A (ko) * | 2022-08-23 | 2025-04-22 | 미네랄리스 테라퓨틱스, 아이엔씨. | 비만 대상체에서 고혈압을 치료하는 방법 |
| CN119789855A (zh) | 2022-09-02 | 2025-04-08 | 爱普宁公司(特拉华) | 治疗睡眠呼吸暂停的方法和组合物 |
| IL327143A (en) * | 2023-09-15 | 2026-05-01 | Mineralys Therapeutics Inc | Process for producing triazine compounds |
| CN120904169B (zh) * | 2024-05-30 | 2026-06-19 | 浙江扬厉医药技术有限公司 | 一种n-烷氧基乙酰胺类化合物、其药物组合物及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015163427A1 (ja) * | 2014-04-24 | 2015-10-29 | 田辺三菱製薬株式会社 | 新規二置換1,2,4-トリアジン化合物 |
| JP2017081911A (ja) * | 2015-10-22 | 2017-05-18 | 田辺三菱製薬株式会社 | 医薬組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2459468T3 (es) * | 2009-05-15 | 2014-05-09 | Novartis Ag | Arilpiridinas como inhibidores de aldosterona sintasa |
| DE102012200360A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
| WO2014179186A1 (en) * | 2013-04-30 | 2014-11-06 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
-
2021
- 2021-10-25 US US18/250,402 patent/US20240009201A1/en active Pending
- 2021-10-25 WO PCT/US2021/056499 patent/WO2022093714A1/en not_active Ceased
- 2021-10-25 JP JP2023525457A patent/JP2023546970A/ja active Pending
- 2021-10-25 EP EP21887273.7A patent/EP4232011A4/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015163427A1 (ja) * | 2014-04-24 | 2015-10-29 | 田辺三菱製薬株式会社 | 新規二置換1,2,4-トリアジン化合物 |
| JP2017081911A (ja) * | 2015-10-22 | 2017-05-18 | 田辺三菱製薬株式会社 | 医薬組成物 |
Non-Patent Citations (2)
| Title |
|---|
| HYPERTENSION, vol. 56, JPN6025053591, 2010, pages 831 - 838, ISSN: 0005765633 * |
| PHARMACOLOGICAL RESEARCH, vol. Vol.154,104311, JPN6025053593, 15 June 2019 (2019-06-15), pages 1 - 12, ISSN: 0005765634 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4232011A1 (en) | 2023-08-30 |
| WO2022093714A1 (en) | 2022-05-05 |
| EP4232011A4 (en) | 2024-11-27 |
| US20240009201A1 (en) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240009201A1 (en) | Cyp11b2 beta hydroxylase inhibitors for hypertension | |
| ES2551877T3 (es) | Rostafuroxina para el tratamiento farmacocinético de afecciones cardiovasculares | |
| JP2020532504A (ja) | 筋ジストロフィーを処置するための方法 | |
| US20100204252A1 (en) | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone | |
| JP7437576B2 (ja) | 乳癌および前立腺癌の処置のための組成物 | |
| WO2021229979A1 (ja) | 脳小血管病の予防又は治療用医薬組成物 | |
| US20250099475A1 (en) | Methods of treating hypertension by periodic suppression of aldosterone synthase | |
| AU2018295387A1 (en) | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| WO2025128614A1 (en) | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder | |
| CN101316626A (zh) | 用于降低血压的方法 | |
| US20260053812A1 (en) | Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic | |
| US20260053811A1 (en) | Methods of treating hypertension in obese subjects | |
| EP4183393A1 (en) | Compounds for treating hepatocellular carcinoma | |
| UA82216C2 (uk) | Лікарський засіб на основі антагоніста рецептора ангіотензину іі та блокатора кальцієвих каналів для профілактики і лікування кардіоваскулярних захворювань | |
| WO2023002362A1 (en) | Treatment of hematological malignancy | |
| AU2007304216B2 (en) | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats | |
| CN107405348A (zh) | Raf抑制剂与紫杉烷的组合 | |
| RU2024129466A (ru) | Белумосудил для лечения хронической дисфункции аллотрансплантата легкого | |
| WO2021142237A1 (en) | Methods for administering lucitanib and combinations thereof | |
| EP4010019A1 (en) | Use of the anti-p-selectin antibody crizanlizumab for treating sickle cell nephropathy and chronic kidney disease associated with sickle cell disease | |
| WO2005073218A1 (ja) | バイパス術に伴う血管攣縮治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241022 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241022 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260106 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260403 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260706 |